Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Anlotinib vs Chemotherapy in Advanced NSCLC
NCT04124731Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Oct 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Phase 2, randomised, open-label trial of sintilimab and anlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: Objective Response Rate up to 24 months. Status: unknown.
02
Drugs
sintilimabanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04124731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04124731.